Literature DB >> 20016245

Puerarin inhibits adhesion molecule expression in tnf-alpha-stimulated human endothelial cells via modulation of the nuclear factor kappaB pathway.

Wenzhi Hu1, Qin Zhang, Xiangjun Yang, Yueying Wang, Lie Sun.   

Abstract

BACKGROUND: The isoflavone puerarin is the most abundant isoflavone-C-glucoside extracted from the root (radix puerariae) of the plant Pueraria lobata and possesses many biological activities. In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.
METHODS: The protein and mRNA levels of tumor-necrosis-factor-alpha (TNF-alpha)-induced ICAM-1, VCAM-1 and E-selectin were determined in HUVECs. Inhibitor kappaB (I-kappaB) phosphorylation and p65 NF-kappaB expression in HUVECs were also examined.
RESULTS: Puerarin inhibited the expression of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin proteins and mRNAs in HUVECs. Subsequently, we determined that the inhibition of ICAM-1, VCAM-1 and E-selectin expression was due to a dose-dependent suppression of phosphorylation and degradation of I-kappaB, which resulted in a reduction of p65 NF-kappaB nuclear translocation.
CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016245     DOI: 10.1159/000264938

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Induction of adhesion molecule expression in co-culture of human bronchial epithelial cells and neutrophils suppressed by puerarin via down-regulating p38 mitogen-activated protein kinase and nuclear factor κB pathways.

Authors:  Ye Liu; Ling-li Shao; Wei Pang; Xiao-mei Lan; Jian-xin Lu; Yu-long Cong; Cheng-bin Wang
Journal:  Chin J Integr Med       Date:  2014-05       Impact factor: 1.978

2.  Paeoniflorin attenuates hepatic ischemia/reperfusion injury via anti-oxidative, anti-inflammatory and anti-apoptotic pathways.

Authors:  Y E Tao; Zhihong Wen; Yingqian Song; Hui Wang
Journal:  Exp Ther Med       Date:  2015-11-27       Impact factor: 2.447

3.  Eupatilin protects against tumor necrosis factor-α-mediated inflammation inhuman umbilical vein endothelial cells.

Authors:  Kai Yu; Xi-Ming Li; Xiao-Lei Xu; Ru-Yan Zhang; Hong-Liang Cong
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 4.  Therapeutic potential of IKK-β inhibitors from natural phenolics for inflammation in cardiovascular diseases.

Authors:  Peng Zhou; Fang Hua; Xiang Wang; Jin-Ling Huang
Journal:  Inflammopharmacology       Date:  2020-01-01       Impact factor: 4.473

5.  Mucoadhesive microparticles for gastroretentive delivery: preparation, biodistribution and targeting evaluation.

Authors:  Jing-Yi Hou; Li-Na Gao; Fan-Yun Meng; Yuan-Lu Cui
Journal:  Mar Drugs       Date:  2014-12-01       Impact factor: 5.118

Review 6.  Molecular mechanisms of isoflavone puerarin against cardiovascular diseases: What we know and where we go.

Authors:  Weida Qin; Jianghong Guo; Wenfeng Gou; Shaohua Wu; Na Guo; Yuping Zhao; Wenbin Hou
Journal:  Chin Herb Med       Date:  2022-03-23

7.  Shinjulactone A Blocks Vascular Inflammation and the Endothelial-Mesenchymal Transition.

Authors:  Ye-Eun Jang; Jenita Immanuel; Jin-Ri Lee; Yu-Jin Jang; Yun Ju Kwon; Hyun Sook Kwon; Jung-Woog Shin; Sanguk Yun
Journal:  J Lipid Atheroscler       Date:  2022-09-15

8.  Metabolic profile of puerarin in rats after intragastric administration of puerarin solid lipid nanoparticles.

Authors:  Cheng-Feng Luo; Ning Hou; Juan Tian; Mu Yuan; Shi-Ming Liu; Long-Gen Xiong; Jian-Dong Luo; Min-Sheng Chen
Journal:  Int J Nanomedicine       Date:  2013-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.